# Sun Pharmaceutical

One product, and it is the first genuinely new mechanism in topical acne treatment in decades — with a label candid enough to state that the mechanism, in acne, is unknown.

- **Canonical:** https://www.30plusskin.care/brands/sun-pharmaceutical
- **Site:** 30+/SKIN — Skincare, published as a spec sheet.
- **Issue:** ISSUE NO. 13 / REV. 2026.10
- **Standing terms:** INDEPENDENT · AFFILIATE-FUNDED · NOT MEDICAL ADVICE

---

## The operation

- **Category:** MANUFACTURED PRESCRIPTION DERMATOLOGY · FDA APPROVED
- **Model:** New Drug Application, manufactured product, retail pharmacy dispensing on a prescriber's script.
- **Products assessed:** 1
- **Mean score:** 72/100
- **Mean disclosure score:** 90/100
- **Pricing:** See each offer and billing period in the product records
- **Brand site:** https://www.sunpharma.com
- **TRADING NAME:** SUN PHARMACEUTICAL INDUSTRIES, INC.
- **MODEL:** NDA → MANUFACTURE → RETAIL PHARMACY
- **RANGE ASSESSED:** 1 PRODUCT
- **REGULATORY STATUS:** FDA APPROVED
- **CLASS:** TOPICAL ANDROGEN RECEPTOR INHIBITOR — FIRST OF ITS KIND
- **SIZE:** 60 G — PUBLISHED
- **IN-USE LIMIT:** DISCARD 1 MONTH AFTER OPENING

## Verdict

One product assessed, so this is a note rather than a pattern. Winlevi is clascoterone 1%, the first topical androgen receptor inhibitor approved for acne, and the only way to act on the androgen pathway in skin without a systemic anti-androgen. For adult women with jawline acne who cannot or will not take spironolactone, that is a real and recent addition.

The tolerability result is the strongest we have recorded against a vehicle arm. Across eight measured local reaction types, none was meaningfully worse on drug than on vehicle, and erythema and skin atrophy were both lower on drug. In a category where every alternative is a controlled burn, a treatment that irritates no more than its own base is a clinical asset in its own right.

The disclosure is unusually candid in three places. The label states that the mechanism of action for acne is unknown. It publishes HPA-axis suppression rates by age group — 5% of adults and 9% of adolescents at day 14 — with the four-week recovery interval. And it publishes the trial demographics, mean age 19.7 and 91% Caucasian, which quietly undercut the adult-female positioning the product is marketed on.

The economics are the problem, and they are stark. Around $509 discounted and $754 at retail for a 60 g tube, refrigerated before dispensing, with an instruction to discard one month after first opening. For most users that means throwing away a substantial fraction of an expensive tube on the label's own instruction. Copay assistance and coverage change the picture entirely, which is itself a reason the sticker price means nothing without checking.

## What the reviewed offering tells us

### 01 — A new mechanism, honestly qualified

'The mechanism of action of WINLEVI cream for the topical treatment of acne vulgaris is unknown.' The receptor biology is established; the causal chain to lesion counts is inference, and the label says so on a product whose entire marketing rests on its mechanism.

### 02 — Irritation no worse than vehicle

Erythema 12.2% on drug against 15.4% on vehicle. Scaling 10.5% against 10.4%. Skin atrophy 1.6% against 2.6%. The vehicle column is also a lesson: between 8% and 15% of people applying a plain cream to acne-prone skin twice daily for twelve weeks reported redness, flaking or itching.

### 03 — Topical does not mean local

HPA-axis suppression in 1 of 20 adults and 2 of 22 adolescents after fourteen days, all recovering within four weeks of stopping, with potassium shifts in 5% against 4% on vehicle and a mean peak plasma concentration of 4.5 ng/mL. Small, reversible and measured — which is precisely what compounded topicals containing hormones or steroids cannot offer.

### 04 — Trialled in teenagers, marketed to adults

Mean trial age 19.7, with 45% of subjects aged 12 to 17 and 91% Caucasian. The receptor is the same receptor and the extrapolation is reasonable, but the evidence for the adult hormonal-acne use this product is positioned around is extrapolation, and the demographic table says so more plainly than any marketing page.

### 05 — A disclosure success punished by an economics failure

Discard one month after opening, or 180 days after dispensing, whichever is sooner — on a 60 g tube costing around $509. The information is right there on the label. It simply converts directly into money the patient throws away.

## Credit where it is due

- First-in-class topical androgen receptor inhibitor.
- Two identically designed vehicle-controlled trials with consistent results and published confidence intervals.
- Local reaction rates published against vehicle across eight reaction types.
- HPA-axis suppression rates published by age group, with the recovery interval.
- Potassium shifts published against vehicle.
- Systemic exposure quantified.
- States plainly that the mechanism of action for acne is unknown.
- Publishes trial demographics that undercut its own positioning.
- States storage and in-use limits explicitly, even though they make the product look worse.

## Disclosure matrix

| Product | CONC. ON PAGE | CONC. FINDABLE | CONTRA-INDICATIONS | SIZE | SIDE EFFECTS |
| --- | --- | --- | --- | --- | --- |
| Sun Pharmaceutical Winlevi | yes | yes | yes | yes | yes |

## Reviews

| No. | Product | Stance | Score | Price | Document |
| --- | --- | --- | --- | --- | --- |
| R-39 | Winlevi — Clascoterone cream 1% | CONDITIONAL | 72/100 | $509 | /reviews/winlevi-clascoterone-cream-review |

---

## PROMOTIONAL SPOTLIGHT: Explore CoreAge Rx skincare

More options for your skin. A patient community to connect with along the way.

**Five skincare options to explore** — Browse CoreAge Rx's prescription skincare range for concerns including fine lines, dark spots, blemishes and more.

**Connect with other patients** — Explore the CoreAge Rx patient community for shared experiences, conversations and support beyond your daily routine.

[CHECK OUT COREAGE RX SKINCARE](https://try.coreagerx.com/skincare?utm_source=30plusskin.care&utm_medium=affiliate&utm_campaign=skincare_reviews&utm_content=reading_footer)

[EXPLORE THE PATIENT COMMUNITY](https://community.coreagerx.com/)

[Read our CoreAge Rx reviews](/reviews/coreage-rx-skincare-review)

Prescription options require a clinician's assessment. Compounded medications are not FDA-approved. Community discussions do not replace medical advice.

[Product range](https://help.coreagerx.com/medication/coreage-rx-prescription-skincare) · [Community information](https://www.coreagerx.com/contact-us/)

[About promotional placements](/disclosure)

---

## Elsewhere in the register

- [Review register](/reviews)
- [Active monographs](/actives)
- [Brand register](/brands)
- [Evidence register](/evidence)
- [The ledger](/ledger)
- [How we test](/how-we-test)
- [Agent guide](/llms.txt)
- [Sitemap](/sitemap.xml)

_SOURCE-BASED ASSESSMENTS. PUBLISHER PREFERENCES ARE IDENTIFIED SEPARATELY._